NNI-351
Jump to navigation
Jump to search
![]() | |
Clinical data | |
---|---|
Routes of administration | By mouth |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C24H24FN5OS |
Molar mass | 449.55 g·mol−1 |
3D model (JSmol) | |
| |
|
NNI-351 is an orally active inhibitor of DYRK1A and neurogenesis enhancer which is under development by NeuroNascent, Inc. for the treatment of Down syndrome, depression, and post-traumatic stress disorder (PTSD).[1][2] As of 2017, it is in the preclinical development stage, and has yet to progress to human clinical trials.[1] In July 2022, NNI-351 was granted orphan drug status by the FDA for the treatment of Fragile X syndrome.[3]
See also
References
- ^ a b "Research programme: Psychiatric and neurological disorders therapeutics - Neuronascent - AdisInsight".
- ^ Froestl W, Muhs A, Pfeifer A (2013). "Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes". J. Alzheimer's Dis. 33 (3): 547–658. doi:10.3233/JAD-2012-121537. PMID 23042218. S2CID 34896894.
- ^ "Neuronascent Receives FDA Orphan Drug Designation for NNI-351 Treatment of Fragile X Syndrome". GlobeNewswire News Room. GlobalNewsWire. 1 June 2022. Retrieved 15 January 2023.
External links
- NNI-351 - NeuroNascent, Inc
- NNI-351 - AdisInsight
- Methods and pharmaceutical compositions for treating down syndrome (patent)
Categories:
- Articles with short description
- Short description matches Wikidata
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Diazepanes
- Ethers
- Experimental drugs
- Fluoroarenes
- Nitriles
- Quinolines
- Thioamides
- Thioketones
- All stub articles
- Nervous system drug stubs